Elan and Wyeth Announce Webcast to Discuss Bapineuzumab Phase 2 Clinical Trial Results
Dublin, Ireland and Madison, NJ . –Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) today announced that the companies will hold a webcast at 6:00 p.m. Central Daylight Time (7:00 p.m. Eastern Daylight Time) on Tuesday, July 29, 2008 with the investment community to discuss the results of the Phase 2 clinical trial of bapineuzumab for Alzheimer’s disease.
Company participants who will discuss the trial results and field questions will include:
· Ron Black, MD, Wyeth Research, Asst. Vice President, Neuroscience.
· Allison Hulme, PhD, Elan, EVP and Head of Global Development.
· Dale Schenk, PhD, Elan, EVP and Chief Scientific Officer.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public.
This event can be accessed by visiting the companies’ web sites at www.elan.com or www.wyeth.com and clicking on the “Investor Relations” icon. Following the live webcast, an archived version of the call and slides will be available at the same URLs.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.